knowledge -WSS

knowledge

author：hotspot 2025-08-27 22:43:13 - browse：241

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Duchenne breakthrough therapy leaves behind pioneering families

entertainment

WSS

Virginia high school admissions case could be legal follow

Hepatitis C has a cure — but many Americans still lack access to it

Decaf coffee targeted by food safety group under obscure FDA rule

Food as medicine: Medically tailored meals may get standardized

Washington mulls new rules to avert another Change Healthcare

What does generative AI mean for health care? We asked experts

focus

knowledge

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

In Memoriam: Notable people who died in 2023

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Hollywood unions extend contract negotiations for actors

Medicare proposal to cover medical devices draws a mixed reaction

Supreme Court strikes down use of affirmative action

Study says nonprofit hospitals fall short in charity care spending

Apple is now the first public company to be valued at $3 trillion

State Dept. review finds Biden bears some blame for Afghanistan failures

leisure time

Roche subsidiary Foundation Medicine opens new headquarters

Dobbs anniversary: the lost opportunity of abortion as health care

Decaf coffee targeted by food safety group under obscure FDA rule

Readout LOUD podcast: mifepristone case, GLP

States should stop sabotaging methadone treatment reform

United colonoscopy coverage change 'may cost lives,' doctors say

entertainment

knowledge

explore

leisure time